search
Back to results

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Primary Purpose

Healthy

Status
Recruiting
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
BI 3000202
Placebo matching BI 3000202
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion criteria Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests without any clinically significant abnormalities Age of 18 to 45 years (inclusive) Body mass index (BMI) of 18.5 to 29.9 kg/m^2 (inclusive) Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Exclusion criteria Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimeter of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm) Any laboratory value outside the reference range that the investigator considers to be of clinical relevance Any evidence of a concomitant disease assessed as clinically relevant by the investigator Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair) Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.

Sites / Locations

  • Humanpharmakologisches Zentrum BiberachRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Experimental

Arm Label

SRD part: Treatment group

SRD part: Placebo group

FE part: Treatment sequence reference (R) - test (T)

FE part: Treatment sequence test (T) - reference (R)

Arm Description

Outcomes

Primary Outcome Measures

SRD part: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator.
This is expressed as the percentage of subjects treated with investigational drug who experience such an event.
FE part: Area under the concentration-time curve of the analyte in plasma over the dosing interval 0 to 24 hours (AUC 0-24)
FE part: Maximum measured concentration of the analyte in plasma (Cmax)

Secondary Outcome Measures

SRD part: AUC 0-24
SRD part: Cmax
FE part: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

Full Information

First Posted
July 7, 2023
Last Updated
July 26, 2023
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT05945888
Brief Title
A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood
Official Title
A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3000202 Administered as Tablet to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Relative Bioavailability Comparison of BI 3000202 as Tablet With and Without Food in Healthy Male Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 25, 2023 (Actual)
Primary Completion Date
November 15, 2023 (Anticipated)
Study Completion Date
November 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The single rising dose (SRD) part of the trial investigates safety, tolerability, and pharmacokinetics of BI 3000202. The food effect (FE) part is conducted to assess the effect of food on the relative bioavailability of the BI 3000202 formulation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
The SRD part of the trial is designed as blinded to subjects, randomised, and placebo-controlled within parallel dose groups. In the FE part, subjects participate in a randomised, open-label, two-way crossover trial part with two treatment periods.
Masking
Participant
Masking Description
SRD part: single blinded FE part: open-label
Allocation
Randomized
Enrollment
68 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SRD part: Treatment group
Arm Type
Experimental
Arm Title
SRD part: Placebo group
Arm Type
Placebo Comparator
Arm Title
FE part: Treatment sequence reference (R) - test (T)
Arm Type
Experimental
Arm Title
FE part: Treatment sequence test (T) - reference (R)
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BI 3000202
Intervention Description
BI 3000202
Intervention Type
Drug
Intervention Name(s)
Placebo matching BI 3000202
Intervention Description
Placebo matching BI 3000202
Primary Outcome Measure Information:
Title
SRD part: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator.
Description
This is expressed as the percentage of subjects treated with investigational drug who experience such an event.
Time Frame
up to 14 days
Title
FE part: Area under the concentration-time curve of the analyte in plasma over the dosing interval 0 to 24 hours (AUC 0-24)
Time Frame
up to 3 days
Title
FE part: Maximum measured concentration of the analyte in plasma (Cmax)
Time Frame
up to 3 days
Secondary Outcome Measure Information:
Title
SRD part: AUC 0-24
Time Frame
up to 3 days
Title
SRD part: Cmax
Time Frame
up to 3 days
Title
FE part: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time Frame
up to 3 days

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests without any clinically significant abnormalities Age of 18 to 45 years (inclusive) Body mass index (BMI) of 18.5 to 29.9 kg/m^2 (inclusive) Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Exclusion criteria Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimeter of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm) Any laboratory value outside the reference range that the investigator considers to be of clinical relevance Any evidence of a concomitant disease assessed as clinically relevant by the investigator Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair) Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Boehringer Ingelheim
Phone
1-800-243-0127
Email
clintriage.rdg@boehringer-ingelheim.com
Facility Information:
Facility Name
Humanpharmakologisches Zentrum Biberach
City
Biberach
ZIP/Postal Code
88397
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Phone
08007234742
Email
deutschland@bitrialsupport.com

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Links:
URL
https://www.mystudywindow.com
Description
Related Info

Learn more about this trial

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

We'll reach out to this number within 24 hrs